Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.
Hong
Soon Jun
SJ
Department of Cardiology, Korea University Anam Hospital, Seoul, Korea.
Kim
Sung Tae
ST
Kim
Tae-Jin
TJ
Kim
Eun-Ok
EO
Ahn
Chul-Min
CM
Park
Jae Hyoung
JH
Kim
Je Sang
JS
Lee
Kyung-Mi
KM
Lim
Do-Sun
DS
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000097:blood; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D054855:Drug-Eluting Stents; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006965:Hyperplasia; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000097:blood; D007328:Insulin / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000473:pathology; D000077205:Pioglitazone; D011446:Prospective Studies; D011474:Prosthesis Design; D054390:Receptors, CCR2 / Q000097:blood; D056910:Republic of Korea; D016037:Single-Blind Method; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D017539:Tunica Intima / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000276:immunology; D018084:Ultrasonography, Interventional
D015415:Biomarkers; D001786:Blood Glucose; D002317:Cardiovascular Agents; D018932:Chemokine CCL2; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D018836:Inflammation Mediators; D007328:Insulin; D015850:Interleukin-6; D008055:Lipids; D000077205:Pioglitazone; D054390:Receptors, CCR2; D020123:Sirolimus; D045162:Thiazolidinediones; C111835:CCL2 protein, human; C515334:CCR2 protein, human; C508600:IL6 protein, human; C517652:hemoglobin A1c protein, human; C489443:zotarolimus